Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of Sinopharm COVID-19 Vaccine Co-administered with Rabies Vaccine
NCT05453487Phase 4Unknown
- Sponsor
- China National Biotec Group
- Start
- Jul 2022
- Primary completion
- Oct 2022
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 4 trial of BBIBP-CorV in coronavirus disease 2019 (COVID-19), sponsored by China National Biotec Group. Status: unknown.
02
Drugs
BBIBP-CorV
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05453487.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05453487.